Elevai Labs Inc (ELAB) Noticias

What the hell going on? I am averaged at $5. Any chances of life?

Nuclear bots going to activate with news AH

They can’t fool us anymore with the bots in short action, Pharma whales going to take bits

Power hour Live The Dream Squeeze

Shorts going to be thought a lesson of a lifetime

Fuck you short criminals, God damn you fucked everyone good till you meet your match to rock and roll

Clan confirmed 3M Outstanding

These short fuckers love to rape retail, well i’m about to get real angry with my clan and clean up the shop

These fuckers love to rape their shareholders

Not even a dead cat bounce for heavens sake, they just brought us to the cleaners after they raped us

Christ what the fuck is going on!!

Grabbed a few down here $2.11 watching for a bigger dip

Don’t sell!!!lock up your shares!!!

Lock up your shares, bull stampede is imminent

They are getting desperate for shares, all holding for massive evaluations

Burn in hell dirty rat short scumbags of the earth

It's a short rat trap, the dirty rat scumbags of the earth will swim in rats vomit

All hold for multi dollars

Pound it now bulls, send it!!!!!!

The dip is in going into strong hands

Big Slaps hitting

$2.63 is first resistance wall

🔥🔥SHORTS TURNED LONG🔥🔥

Super tight hands here, it can fly big

Hold up the fort dude!!!

🔥🔥🔥BURN DOWN ALL RESISTANCE WALLS 🔥🔥🔥

KILL THE SHORTS ROAD SHOW UNDERWAY🔥🔥🔥🔥

Support building up, buy pressure coming in!! dude!!!

🔥🔥LONG LONG TO THE MOON🚀🚀🚀🚀🚀

🔥🔥🔥🔥MOASS🔥🔥🔥🔥

Get ready bulls ask is going to get hit hard

The tides about to turn forest green

Load and hold on the runway ready for takeoff

ready to breakout dudes!!! Strap on your dildo shorts going get it hard

Get ready bulls we going to fly

Time to slap the ask before she lifts off

Clear Blue skies dudes!!! Don’t look up without your sunglasses

It’s screaming huge gap up short squeeze dudes

Time to load the boat dudes!!

CURRENT PRICE
2.41, not at support or resistance
SUPPORT BELOW
None.
RESISTANCE ABOVE
+83.5% at 4.42 ± 0.65 type single, strength 8
+739% at 20.23 ± 2.97 type triple, strength 10
+1872% at 47.53 ± 6.99 type single, strength 1
...
Long TradeLong trade indicators
90%Trade Quality

Long

when wee force 4.42 no resistance untill 20.23 big resistance if by a miracle or fomo we cross this resistance next one is
47.53 very small one and then DRUG MOVE TYPE INITIATED AT 50

E-Trade back online and all numbers updated. It's go time tomorrow and Monday.

So I thought I would try some Dana graphics on ELAB, but I couldn't find any relative to what I was looking for. I kept getting an error saying there is no Dana...
Only Zuul.
Smile folks...It's about time to head to brighter horizons into blue skies$$$

Suspect tomorrow will be the beginning of a multi day squeeze. I will be going in heavily on this one

We are going parabolic brothers🚀🚀🚀🚀

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) --

EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines
The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025
Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments. EL-22 may offer an importation solution by preserving muscle mass while reducing fat mass
Elevai Biosciences Inc. (“Elevai Biosciences”), a subsidiary of Elevai Labs Inc. (NASDAQ: ELAB) (the “Company” or “Elevai”), today announced that it has engaged KCRN Research, Inc., a global contract research organization (CRO), to support the Company’s initial efforts to prepare for an Investigational New Drug (“IND”) application to the FDA for EL-22 in the treatment of obesity and muscle loss preservation.

KCRN specializes in bridging the regulatory gap for Korean-originated assets like EL-22 and preparing early phase drug development projects for the FDA. The Company and CRO partner KCRN are gathering the development work required for the IND submission, including preparing and scheduling a pre-IND meeting with the FDA to determine the path forward for EL-22. The Company intends to complete an IND submission in 2025 and to initiate clinical trials in the U.S. to evaluate the myostatin approach in combination with one or more GLP-1 receptor agonists in obesity.

“Myostatin is currently being pursued as a leading approach for muscle preservation in clinical trials with GLP-1 medications,” said Deniel Mero, Co-founder of Elevai Biosciences. “We are excited by this validated pathway and look forward to KCRN’s support in preparing EL-22 for IND submission. We think this collaboration is the first step to preparing EL-22 for eventual clinical trials and KCRN’s familiarity and experience with both the FDA and our asset make them an ideal CRO partner.”

EL-22, an engineered probiotic expressing myostatin on its surface, targets a clinically validated myostatin pathway that plays an important role in regulating muscle. Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1. The Company believes that EL-22 offers a differentiated, oral approach as compared to other injection myostatin strategies being tested in obesity. It is believed that the mechanism of EL-22 induces mucosal immunity through the body’s own anti-myostatin antibodies and has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.

“We are delighted in our continued support of Elevai and their myostatin program,” said Hugh Lee, CEO & Founder of KCRN. “We are hopeful that this work may result in a new treatment option for the millions of GLP-1 patients in need of a way to preserve muscle.”

Nobel prize clinical trial Micro-RNA Revolution
https://www.elevaibio.com/

A New Treatment Paradigm: Next-Generation Obesity Treatment
Our clinical-stage lead candidate, EL-22, activates the body’s own immune system to inhibit myostatin, a negative regulator of muscle growth.

Data suggests that blocking myostatin causes muscle cell growth and increases muscle power. Combining this muscle targeting approach with existing GLP-1 therapies for weight-loss could have significant promise and a lasting impact in helping obese patients lose fat, while preserving lean muscle mass.

It’s a nobel prize Micro RNA FDA clinical trials for fast track status for obesity world wide

Imagine having 250M volume a day on a 2.5M low floater! Round 2 is going to be massive.

Happy thanksgiving brothers and sisters 🚀God bless ELAB🚀🚀Micro RNA Nobel prize breakthrough 🚀🚀